Roche could rethink $50B US expansion plan if new policies ‘harm’ operations

Title

Roche May Reconsider $50B U.S. Expansion Amid Potentially Harmful Policy Changes

Roche has announced a major plan to invest $50 billion over five years to expand its pharmaceutical and diagnostics manufacturing presence in the United States, building new and expanded facilities across multiple states4 3 1.
The expansion will include at least four new manufacturing facilities, covering next-generation weight-loss medicines, a gene therapy site in Pennsylvania, an R&D center in Massachusetts, and a glucose monitoring products plant, among other initiatives2 5.
Roche’s U.S. investment is expected to create over 12,000 jobs, including construction and operational roles, and expand its workforce beyond the current 25,000 employees across 24 sites in eight states4 3 5.
The investment underscores Roche’s commitment to the U.S. as a key market for research, innovation, and manufacturing, with the company emphasizing its 110-year legacy in the country4.
However, Roche has indicated that its expansion plan depends on a stable and favorable policy environment. The company may review or rethink its investment if new legislation or regulations “harm our industry’s ability to operate and innovate,” though specific policies have not been cited.
The investment comes amid broader industry concerns over trade policies and tariffs, with Roche aiming to bolster its U.S. manufacturing footprint and mitigate global supply chain risks, including those posed by ongoing trade tensions3 5 2.